All News
Filter News
Found 253 articles
-
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
-
Ka-ching! Gilead Ends Year With Two Major Deals That Could Total More Than $3.125 Billion
12/20/2018
Gilead Sciences, in two days, inked two collaboration deals with two different companies that could pay out an aggregate of more than $3.125 billion. One of those deals is in the area of immuno-oncology, the other in fibrosis. -
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
12/19/2018
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.
-
Third Rock Ventures Names Christoph Lengauer, Ph.D., and Jeffrey Tong, Ph.D., as Partners
12/13/2018
Scientific and strategic leaders bring significant operating experience to the firm’s company creation mission
-
Scholar Rock to Present Preclinical Data Highlighting the Role of TGFβ1 Inhibition in Overcoming Checkpoint Resistance at the SITC Annual Meeting
10/1/2018
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that new preclinical data from its TGFβ1 cancer immunotherapy program will be presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 9-11, 2018 at the Walter E. Washington Convention Center in Washington DC.
-
Biotechnology company Morphic Therapeutic has just publicized their completion of a successful $80 million Series B financing meant to support their two lead programs in developing modern oral integrin therapies, as well as further other clinic programs.
-
PPG Foundation Invests Nearly $150,000 in Northeastern Ohio Educational, Community Programs
9/6/2018
PPG (NYSE:PPG) today announced that the PPG Foundation recently invested nearly $150,000 in 23 northern Ohio organizations in support of educational and community sustainability programs.
-
August 31 Research Roundup: New Brain Cells, Regrowing Spinal Nerve Cells, Stunted Telomeres and ...
8/31/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
-
Scholar Rock Appoints Rhonda Chicko as Chief Financial Officer
4/9/2018
Company strengthens leadership team with appointments and promotions in key roles for next stage of growth.
-
Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
3/29/2018
SRK-015 is an inhibitor of the activation of myostatin, which Scholar Rock believes has the potential to be the first muscle-directed therapy to reverse or prevent muscle atrophy in SMA patients.
-
Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015, a Novel Inhibitor of Myostatin Activation, Supporting the Treatment of Muscle Atrophy Disorders
2/2/2018
The preclinical research published today by Scholar Rock researchers demonstrates that inhibiting the activation of the latent precursor form of myostatin using monoclonal antibodies offers a potentially superior approach to address this important therapeutic target.
-
Scholar Rock and Collaborators at Harvard Medical School and Northeastern University Elucidate Molecular Basis of Myostatin Activation - a Key Physiological Process in Muscle Health
1/23/2018
Myostatin (also known as GDF8) is a key signaling protein that contributes to the regulation of muscle mass and function.
-
The round was led by new investor Invus, with participation of another new investor, Redmile Group.
-
Scholar Rock Announces Issuance Of Broad Patent Covering Therapeutic Approach For Neuromuscular Diseases
9/14/2017
-
Scholar Rock Appoints Heather Faulds As Vice President Of Regulatory Affairs
9/14/2017
-
Scholar Rock And The Miami Project To Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential Of SRK-015 In Spinal Cord Injury At 35th Annual National Neurotrauma Symposium
7/10/2017
-
Scholar Rock Appoints David L. Hallal As Chairman Of Board Of Directors
7/6/2017
-
Scholar Rock To Develop SRK-015 To Improve Muscle Function In Patients With Spinal Muscular Atrophy
6/28/2017
-
Adimab LLC. Provides Mid-Year Update On 2017 Partnership Activity
6/21/2017